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Introduction
Paraneoplastic chorea is a rare hyperkinetic movement disorder caused 
by remote effects of  the underlying neoplasm on the basal ganglia.1 
Anti-CV2/CRMP5 autoantibody is the most commonly detected 
anti-neuronal autoantibody.2 Patients with typical paraneoplastic chorea 
show fully developed chorea in the course of  weeks to months with acute 
inflammation in the striatum.1,2 Median survival period depends on the 
underlying cancer and related antibody but generally ranges from 10 to 
20 months.3,4 Regarding the treatment approach, the best option for 
symptomatic management remains unclear. We reported a case of  
anti-CV2/CRMP5 autoantibody positive paraneoplastic chorea present-
ing with insidious onset and slow progression, decreased striatal volume 
on serial follow-up magnetic resonance imaging (MRI), effectively man-
aged with intravenous amantadine prior to anti-cancer management.
Case report 
A 63-year-old man presented at our clinic with slowly progressive 
chorea starting from the neck of  1-year duration. The patient was a 60 
pack-year smoker with hypertension and was undergoing a statin drug 
treatment for dyslipidemia at the time of  presentation. In anamnesis, 
there was no family history of  movement disorder or stroke, or evidence 
of  recent infection or weight change; slow development of  chorea that 
had spread to the right arm and affected gait as a consequence was 
noted. Initially, chorea was managed with clonazepam (1 mg/d) and 
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Abstract
Background: Paraneoplastic chorea is typically a subacute progressive hyperkinetic movement disorder. The mainstay of  treatment is managing the underlying 
neoplasm. However, the clinical course may be variable, and effective symptomatic management can precede the start of  cancer treatment.
Case report: A 63-year-old man presented with insidious onset, slowly progressive generalized chorea for 1 year, later diagnosed as anti-CV2/CRMP5 autoanti-
body positive paraneoplastic chorea. His chorea was markedly improved with intravenous amantadine.
Discussion: In patients with anti-CV2/CRMP5 autoantibody-related chorea, sequential follow-up of  brain magnetic resonance imaging reveals progression from 
active inflammation to atrophy. Our report highlights the efficacy of  intravenous amantadine in paraneoplastic chorea.
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haloperidol (1.5 mg/d). At post-treatment, mild improvement of  
symptoms was observed initially with gradual worsening over the next 
6 months. After increasing the dose of  haloperidol, the improvement 
of  chorea was achieved, but the development of  Parkinsonism as a 
side effect was noted. Therefore, haloperidol was switched to queti-
apine (400 mg/d), but the relapse of  chorea was observed. When the 
patient was referred to our clinic 12 months after the symptom onset 
(Video 1), his previous medical records were not accessible.
On the brain MRI images acquired at 12 months after the symptom 
onset, marked bilateral striatal atrophy was observed (Figure 1B). 
Peripheral blood smear, fasting glucose, and glucose tolerance test were 
unremarkable. Tumor markers, including carcinoembryonic antigen, 
prostate-specific antigen, and carbohydrate antigen 19-9 were normal. 
Genetic tests for spinocerebellar ataxia type 17 and Huntington’s dis-
ease were negative. In the results of  detailed neuropsychiatric cognitive 
assessment (Seoul Neuropsychological Screening Battery, 2nd edition),5,6 mild 
cognitive impairment was revealed especially regarding frontal lobe 
function. In addition, mild depression was noted in the abbreviated ver-
sion of  Geriatric Depression Scale (6/15).7
After initial work-up at our clinic, we were able to assess the previ-
ous brain MRI scans acquired 4 months after the symptom onset. 
T2-hyperintensities were present in the bilateral caudate nucleus 
and anterior putamen (Figure 1A). On the [18F] N-(3-fluoropropyl)- 
2β-carbomethoxy-3β-(4-iodophenyl) nortropane (FP-CIT) positron 
Figure 1.  Structural and Functional Imaging of  the Patient’s Brain. Brain MRI nonenhanced T2 FLAIR images acquired 4 months (A) and 12 months 
(B) after initial symptom showed marked striatal hyperintensity and striatal atrophy, respectively, and FP-CIT PET scan showed a decrease in DAT binding in the 
bilateral striatum (C). Abbreviations: [18F] N-(3-fluoropropyl)-2β-carbomethoxy-3β-(4-iodophenyl) nortropane (FP-CIT) positron emission tomography (PET); DAT, 
Dopamine Active Transporter; FLAIR, Fluid Attenuated Inversion Recovery; MRI, Magnetic Resonance Imaging.
Video 1.  Before Intravenous Amantadine Treatment. Chorea mainly 
involving the face, neck, and both upper extremities, with mild involvement of  
the lower extremities while sitting down with feet touching the floor is observed. 
Slight loss of  balance and augmentation of  chorea is noted when performing the 
pull-test. Wide-based choreiform gait with irregular step length differential is 
seen during free gait.
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emission tomography (PET) scan, decreased uptake in the bilateral 
striatum, especially in the caudate nucleus was obtained (Figure 1C). 
The anti-CV2/CRMP5 autoantibody was tested positive in a qualita-
tive analysis using serum and cerebrospinal fluid mixture. Meanwhile, 
the diagnosis of  small cell lung cancer with metastasis in the lymph 
node, first lumbar spine, and left ureter was made based on the malig-
nancy workup.
Before any treatment plan for the lung cancer was implemented, 
intravenous amantadine (200 mg in 500 cm3 of  normal saline given 
over a 3-hour period, twice per day for 5 days) was administered to 
manage chorea; in response, remarkable improvements in chorea, 
especially of  the limbs and trunk were attained, and consequently, 
the patient’s gait was improved (Video 2). We confirmed the efficacy 
and safety of  drug treatment in our patient and made the switch 
from intravenous amantadine to oral amantadine (200 mg/d). At the 
outpatient clinic, the dose of  oral amantadine was increased from 
200 to 300 mg/d, and beneficial effect of  the treatment was main-
tained at 3 years’ follow-up.
Discussion
We reported a case of  slowly progressive generalized chorea associ-
ated with metastatic small cell lung cancer. We demonstrated a change 
from active inflammatory state to atrophy through serial MRI and 
suggested the effectiveness of  IV amantadine in treatment of  the 
patient’s chorea.
Orolingual chorea and retrocollis may resemble tardive dyskinesia. 
However, at an initial visit with the attending physician (JH Lee), the 
patient reported no prior exposure to any antiemetic or antipsychotic 
medication and was experiencing milder form of  chorea that was com-
patible with hyperkinetic movements observed in our clinic 12 months 
later (Video 1). Subsequently, the patient underwent treatment with hal-
operidol, which initially showed improvement of  chorea. Based on these 
facts, we considered that chorea in our patient was due to paraneoplas-
tic syndrome and not tardive dyskinesia.
Brain MRI performed 12 months after the symptom onset revealed 
severe atrophy in the striatum, most prominently involving bilateral 
head of  the caudate nuclei. Subsequently, we assessed the brain 
MRI scans acquired previously at other hospitals and observed 
T2-hyperintensities in the identical regions, which agree with the 
 findings of  another report of  cases of  paraneoplastic chorea with 
 positive anti-CV2/CRMP5 autoantibody that included changes of  
T2-hyperintenssity in the basal ganglia.2 Moreover, FP-CIT PET 
revealed decreased uptake of  dopamine transporter which may be asso-
ciated with severe striatal atrophy (Figure 1B), a finding most likely 
explained as a remnant of  active inflammation (Figure 1A). Persistence 
of  atrophic landmarks after inflammation suggests pathophysiology 
involving irreversible cytotoxic process. Previous studies have reported 
presynaptic dopaminergic deficit in patients with hyperglycemic chorea 
and Huntington’s disease,8,9 but not in those with paraneoplastic chorea 
with anti-CV2/CRMP5 autoantibody. To the best of  our knowledge, 
this is the first case report to present a time-series follow-up brain MRI, 
with conclusive FP-CIT PET scan finding of  decreased presynaptic 
dopaminergic uptake in the bilateral striatum in a patient with parane-
oplastic chorea.
Immunomodulatory therapy with intravenous immunoglobulin 
and steroids achieved some success in the control of  chorea in 
patients with paraneoplastic chorea; however, there is no consensus 
on symptomatic management in such cases.10,11 Few randomized pla-
cebo-controlled trials on treatment with amantadine are reported for 
Huntington’s disease.12,13 Studies have indicated that the pathophys-
iology of  chorea in Huntington’s disease can be explained by imbal-
ance between indirect and direct pathways due to selective 
involvement of  indirect pathway.14 We considered that the effective-
ness of  amantadine on chorea of  anti-CV2/CRMP5-related cho-
rea was due to modulation of  the imbalance between direct and 
indirect pathways in the basal ganglia by two possible mechanisms: 
(1) decrease of  glutaminergic input from the neocortices and conse-
quently, decrease of  total motor output, and (2) sensitization of  the 
globus pallidus pars interna (GPi) to glutaminergic input and aug-
mentation of  inhibitory response at the thalamus. Clinicians should 
consider IV amantadine as a low-cost alternative treatment to con-
trol activity-limiting severe chorea in patients with paraneoplastic 
chorea before initiating other immunomodulatory therapy or cancer 
treatment.
One of  the limitations of  our case report was that our antibody test-
ing was performed only in a qualitative manner. Nevertheless, the 
method was already validated in previously published literature.15 
Future studies focused on changes of  autoantibody titers before and 
after treatment with amantadine are needed.
In conclusion, the findings of  time-series follow-up brain MRI in 
anti-CV2/CRMP5 autoantibody-related chorea indicated the change 
from active inflammation to atrophy according to the clinical course, 
which may reflect the mechanisms involved in pathophysiology of  the 
disease. Moreover, IV amantadine showed potential as a viable option 
for symptomatic management in anti-CV2/CRMP5 autoantibody- 
related paraneoplastic chorea.
Video 2.  After Intravenous Amantadine Treatment. Partial improvement 
of  chorea involving the face, neck, and both the upper extremities and some resto-
ration in gait and postural balance is observed. At follow-up interview on symp-
toms, the patient reported improvement in using spoon while eating and in gait.
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